CellaVision ABCHIX:CEVIS 95 Net Current Asset Value is kr10.53 as of Mar. 2026, which is 100% below its 10-year median of 32.77. GuruFocus rates CHIX:CEVIS with a GF Score™ of 95/100 and a GF Value™ of kr249.12. The stock has 1 warning sign investors should review. Among 566 Medical Devices & Instruments companies, CellaVision AB ranks worse than 77.74% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
CellaVision AB's net current asset value per share for the quarter that ended in Mar. 2026 was kr10.53.
The historical rank and industry rank for CellaVision AB's Net Current Asset Value or its related term are showing as below:
CHIX:CEVIs'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 10.49 Med: 32.77 Max: 334.52
Current: 12.92
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of CellaVision AB was 334.52. The lowest was 10.49. And the median was 32.77.
CHIX:CEVIs's Price-to-Net-Current-Asset-Value is ranked worse than 77.74% of 566
companies
in the Medical Devices & Instruments industry
Industry Median: 5.05
vs CHIX:CEVIs: 12.92
CellaVision AB (CHIX:CEVIs) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
CellaVision AB Net Current Asset Value Related Terms
CellaVision AB Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for CellaVision AB's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:CEVIS vs ABT, SYK, MDT: Net Current Asset Value Comparison
For the Medical Devices subindustry, CellaVision AB's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellaVision AB Price-to-Net-Current-Asset-Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CellaVision AB's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where CellaVision AB's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of kr10.53 mean?
CellaVision AB (CHIX:CEVIS) has a Net Current Asset Value of kr10.53 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on CellaVision AB and its competitors. This is 68% below median its historical median of 32.77. Over the past decade, CellaVision AB's Net Current Asset Value has ranged from 10.49 to 334.52. According to the industry distribution chart, CellaVision AB ranks #440 out of 566 companies in the Medical Devices & Instruments industry, placing it in the top 77.7%.
Is CellaVision AB's Net Current Asset Value too high?
CellaVision AB's current Net Current Asset Value of kr10.53 is 68% below median its 10-year median of 32.77. Over the past 10 years, this metric has ranged from a low of 10.49 to a high of 334.52. Based on the distribution chart, CellaVision AB ranks #440 out of 566 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, CellaVision AB has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does CellaVision AB's Net Current Asset Value compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, CellaVision AB ranks #440 out of 566 companies for Net Current Asset Value. This places CellaVision AB in the lower half of its industry. The industry median Net Current Asset Value is 5.05. Historically, CellaVision AB's own Net Current Asset Value has ranged from 10.49 to 334.52 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Medical Devices & Instruments company?
The median Net Current Asset Value among Medical Devices & Instruments companies is 5.05, based on 566 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on CellaVision AB and its competitors. For the Medical Devices & Instruments industry, the median Net Current Asset Value is 5.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CellaVision AB's current Net Current Asset Value is kr10.53, which is 68% below median its own 10-year median of 32.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellaVision AB stock overvalued right now?
CellaVision AB (CHIX:CEVIS) has a current Net Current Asset Value of kr10.53. The stock's GF Value™ is kr249.12, compared to a current price of kr160.20 — trading 35.7% below its estimated fair value. The current Net Current Asset Value is kr10.53, which is 68% below median its 10-year median of 32.77. CellaVision AB's overall GF Score™ is 95/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For CellaVision AB (CHIX:CEVIS), the current Net Current Asset Value is kr10.53 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellaVision AB (CHIX:CEVIS) Overvalued in 2026?
Based on GuruFocus' analysis, CellaVision AB stock appears to be undervalued.
The current stock price of kr160.20 is trading 35.7% below its estimated GF Value™ of kr249.12.
Key valuation signals for CHIX:CEVIS:
Net Current Asset Value: kr10.53 (68% below median its 10-year median of 32.77)
GF Value™: kr249.12 vs. price of kr160.20 (35.7% below fair value)
No single metric tells the full story. See the CHIX:CEVIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellaVision AB is engaged in developing and selling instruments, software, and reagents for blood and body fluid analysis. The company automates parts of the sample preparation process and replaces manual microscopes with instruments based on digital image analysis technology and artificial intelligence. The solutions contribute to more effective workflows and higher quality in laboratory medicine. The product offer consists of products and solutions for standardized laboratory diagnostics and improved performance for cellular image processing and systems for digital microscopy in hematology, consisting of reagents, instruments, and supplementary software and peripheral equipment.
95GF Score
Get the complete analysis for CHIX:CEVIS
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:CEVIS has been successfully added to your 
